This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.  
  • Delicious




Swiss Life Launches New Investment Fund For Biomed Stocks

Ulrika Lomas, Tax-news.com, Brussels

08 January 2001

Together with three former partners from the Bellevue Group, Swiss Life Asset Management has created an investment fund for biomed (biological and medical-based technology) stocks.

According to a statement released by the Swiss Life/Rentenanstalt Group, Adamant Biomedical Investments is the first of its kind as an investment management company focusing on a combination of world-wide investments in the rapidly expanding biomed industry where growing opportunities for investment are being forecast. Swiss Life Asset Management will own 51% of the new company with the possibility of a future listing on the stock exchange.

The aim behind the company, says Swiss Life, is to offer a strategy to investors that will provide them with a first-class range of traditional asset management services including bespoke solutions as well as access to innovative investment sectors which show substantial prospects for future growth. This is due to the support of a global network of experts in clinical research. In addition to this Swiss Life states that the company will also have acess to first-class contacts within specialist firms in the biomed sector.

Swiss Life is confident that Adamant's combination of entrepreneurial culture, financial strength and sound business environment is a winning formula which will rapidly develop the company into one of the leading European providers in the biomed industry.

.

 

 






Write a comment